药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）

2021-02-10 国家药品监督管理局药品审评中心（CDE） NMPA

原发免疫性血小板减少症

静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）

中文标题：

静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）

发布机构：

国家药品监督管理局药品审评中心（CDE）

发布日期：

2021-02-10

简要介绍：

静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）

相关资料下载：
[AttachmentFileName(sort=1, fileName=66.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2cf2d1c002062084, title=静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）, enTitle=, guiderFrom=NMPA, authorId=0, author=, summary=静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）, cover=, journalId=0, articlesId=null, associationId=1936, associationName=国家药品监督管理局药品审评中心（CDE）, associationIntro=国家药品监督管理局药品审评中心（CDE）, copyright=0, guiderPublishedTime=Wed Feb 10 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p>静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（试行）</p>, tagList=[TagDto(tagId=4183, tagName=原发免疫性血小板减少症)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=67, categoryName=研究设计与统计, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=0, guiderKeyword=, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指导原则, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=20, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=25108, appHits=209, showAppHits=0, pcHits=868, showPcHits=24899, likes=1, shares=12, comments=12, approvalStatus=1, publishedTime=Fri Feb 19 22:50:28 CST 2021, publishedTimeString=2021-02-10, pcVisible=1, appVisible=1, editorId=4754896, editor=fbzhang, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=fbzhang, createdTime=Fri Feb 19 22:50:24 CST 2021, updatedBy=4754896, updatedName=fbzhang, updatedTime=Sat Jan 06 08:46:49 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=66.pdf)])
66.pdf
下载请点击：
评论区 (10)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1058131, encodeId=2dc610581318e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:11:59 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996447, encodeId=6dd399644eda, content=需要20分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/99ca4d710e5749c2bf0f02f899f9a03e/ccb1a84573d345f0b002b0175599eda5.jpg, createdBy=bb155541842, createdName=叶子1914, createdTime=Mon Jul 05 15:58:47 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971886, encodeId=317b9e1886dd, content=需要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:42 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971885, encodeId=9cac9e188528, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971884, encodeId=eb739e188428, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:31:22 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-10-06 1242a32cm95暂无昵称

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1058131, encodeId=2dc610581318e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:11:59 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996447, encodeId=6dd399644eda, content=需要20分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/99ca4d710e5749c2bf0f02f899f9a03e/ccb1a84573d345f0b002b0175599eda5.jpg, createdBy=bb155541842, createdName=叶子1914, createdTime=Mon Jul 05 15:58:47 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971886, encodeId=317b9e1886dd, content=需要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:42 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971885, encodeId=9cac9e188528, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971884, encodeId=eb739e188428, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:31:22 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-07-05 叶子1914

    需要20分

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1058131, encodeId=2dc610581318e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:11:59 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996447, encodeId=6dd399644eda, content=需要20分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/99ca4d710e5749c2bf0f02f899f9a03e/ccb1a84573d345f0b002b0175599eda5.jpg, createdBy=bb155541842, createdName=叶子1914, createdTime=Mon Jul 05 15:58:47 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971886, encodeId=317b9e1886dd, content=需要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:42 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971885, encodeId=9cac9e188528, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971884, encodeId=eb739e188428, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:31:22 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 787197690

    需要积分

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1058131, encodeId=2dc610581318e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:11:59 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996447, encodeId=6dd399644eda, content=需要20分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/99ca4d710e5749c2bf0f02f899f9a03e/ccb1a84573d345f0b002b0175599eda5.jpg, createdBy=bb155541842, createdName=叶子1914, createdTime=Mon Jul 05 15:58:47 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971886, encodeId=317b9e1886dd, content=需要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:42 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971885, encodeId=9cac9e188528, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971884, encodeId=eb739e188428, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:31:22 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 787197690

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1058131, encodeId=2dc610581318e, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d5e82466251, createdName=1242a32cm95暂无昵称, createdTime=Wed Oct 06 16:11:59 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996447, encodeId=6dd399644eda, content=需要20分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210705/99ca4d710e5749c2bf0f02f899f9a03e/ccb1a84573d345f0b002b0175599eda5.jpg, createdBy=bb155541842, createdName=叶子1914, createdTime=Mon Jul 05 15:58:47 CST 2021, time=2021-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971886, encodeId=317b9e1886dd, content=需要积分, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:42 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971885, encodeId=9cac9e188528, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:32:03 CST 2021, time=2021-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=971884, encodeId=eb739e188428, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38474809008, createdName=787197690, createdTime=Tue Jun 08 16:31:22 CST 2021, time=2021-06-08, status=1, ipAttribution=)]
    2021-06-08 787197690

    很好

    0

以上为热门评论，梅斯医学App还有更多内容

相关指南

成人原发免疫性血小板减少症诊断与治疗中国指南（2020年版）

中华医学会血液学分会血栓与止血学组 · 2020-08-30

静注人免疫球蛋白治疗原发免疫性血小板减少症临床试验技术指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2020-07-16

2016 成人原发免疫性血小板减少症诊断与治疗中国专家共识

中华医学会血液学分会血栓与止血学组 · 2016-02-29